The diverse advanced treatment modalities currently available to children with medulloblastoma, including surgery and radiotherapy, are associated with deleterious side effects and often with an unfavorable prognosis. A mutant adenovirus, Delta-24, which has a 24-base pair deletion in the Rb-binding region of the E1A gene, demonstrates selective replication and oncolysis in various malignant phenotypes. Here we report the ability of Delta-24 to kill medulloblastoma cells. Flow cytometric analyses of cell receptors demonstrated expression of the coxsackie adenovirus receptor and RGD-related integrins in the assessed medulloblastoma cell lines. Infectivity assays using a replication-deficient adenovirus to transduce the green fluorescence protein gene showed that the Delta-24 adenovirus infects 99% of Daoy and 46% of D283 Med medulloblastoma cells at a multiplicity of infection (MOI) of 50. Within 4 days after infecting medulloblastoma cells with Delta-24, a noticeable cytopathic effect was produced. Delta-24 induced a total cytopathic effect in Daoy and D283 Med medulloblastoma cells after 6 and 8 days of infection, respectively. In the infected population of cells, cell death correlated with the accumulation of cells in the S phase. At 5 days postinfection with 2.5 MOIs of Delta-24 adenovirus, the percentage of Daoy medulloblastoma cells in the S phase increased to 71.975.5%, compared with control values of 20.571.4%. The release of viral progeny was quantified as being increased by two orders of magnitude, indicating efficient replication of Delta-24 in medulloblastoma cells. This is the first report of the ability of oncolytic adenoviruses to infect and kill medulloblastoma cells, the findings of which suggest the potential efficacy of Delta-24 as a therapy for human medulloblastoma tumors. Cancer Gene Therapy ( Survivors of this tumor are often left with serious adverse effects from currently applied therapies. These include surgery, frequently in areas adjacent to centers in the brain that control essential vital functions, and radiotherapy, which can cause cognitive dysfunction and growth complications.
M edulloblastoma is the most common brain tumor in children and is a challenging therapeutical problem. 1 Survivors of this tumor are often left with serious adverse effects from currently applied therapies. These include surgery, frequently in areas adjacent to centers in the brain that control essential vital functions, and radiotherapy, which can cause cognitive dysfunction and growth complications. [2] [3] [4] These deleterious side effects have impelled the search for novel therapies for these tumors.
Recent attempts to demonstrate the selectivity and efficiency of genetically engineered type 5 adenoviruses with oncolytic properties were successful in different human cancers. 5 After the seminal work from McCormick's laboratory, 6 several groups became interested in studying oncolytic adenoviruses. We demonstrated that the Delta-24 oncolytic adenovirus could selectively replicate in and efficiently kill glioma cells. 7, 8 Importantly, this adenovirus replicates exclusively in cells with downregulated pRb function or abnormal cell cycle control mechanisms. 7 The clinical experience with oncolytic adenoviruses, using either local or systemic administration of the adenovirus to human tumors, confirmed its safety and produced encouraging results. 9 The ability to use a local, intratumoral approach to medulloblastoma therapy with an oncolytic virus that selectively kills malignant cells would provide obvious advantages by eliminating the surgical burden and complications resulting from invasive procedures, which are particularly harmful to the smaller brains of pediatric patients. A recent publication by Yang et al demonstrated the benefits of replication-competent reovirus therapy for medulloblastoma, 10 a finding that is theoretically aligned with the potential usefulness of oncolytic adenoviruses in a pediatric medulloblastoma population.
Our goal was to identify medulloblastoma tumors as novel and suitable targets for oncolytic adenoviruses engineered to replicate exclusively in cells with an abnormal regulation of cell progression at the G1/S checkpoint, and we succeeded in demonstrating that the Delta-24 adenovirus produced substantial oncolytic activity in medulloblastoma cell lines. To our knowledge, this study is the first to characterize the oncolytic potential of the Delta-24 replication-competent adenovirus in human medulloblastoma. Accordingly, we quantified the expression of key adenovirus receptors in medulloblastoma cell and demonstrated that they were capable of being efficiently infected by the Delta-24 oncolytic adenovirus. The oncolytic effect of the adenovirus was demonstrated by decreased cell viability, as assessed by crystal violet, trypan blue, and MTT assays and the induction of S phase. The demonstrated cytopathic effect (CPE) was consistent with efficient replication of the adenovirus in the cancer cells. Our results show that replication-competent adenovirus could be used as an anticancer agent in medulloblastomas.
Materials and methods

Reagents
Cell culture grade antibiotics, penicillin G sodium, streptomycin sulfate and amphotericin B were provided by Invitrogen (Carlsbad, CA). Fetal bovine serum (FBS), crystal violet, trypan blue (0.4% solution), 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT) were from Sigma-Aldrich (St Louis, MO).
Cell lines and infection conditions
The human medulloblastoma cell lines Daoy and D283 Med were obtained from the American Type Culture Collection (Manassas, VA). Human embryonic kidney 293 QBI cells, Ad5 E1 transformed (transformed by sheared human adenovirus type 5 [Ad 5] DNA), were purchased from Qbiogene (Carlsbad, CA). Normal human astrocytes (NHAs) were purchased from Clonetics/ BioWhittaker (Walkersville, MD). The cell culture conditions were maintained according to the manufacturer's recommendations. The cell lines were grown as a monolayer and were maintained at 371C in a humidified atmosphere containing 7% CO 2 . NHA cultures were maintained in astrocyte growth medium from an AGMAstroctye Medium BulletKit obtained from Clonetics/ BioWhittaker. For serum starvation conditions, we grew NHAs at a low density (2 Â 10 4 per well in a six-well plate) in the medium with 0.5% fetal bovine serum and no growth supplements. The cell lines were infected as described previously. 11, 12 Briefly, medulloblastoma cell cultures were incubated for half an hour in serum-free media with a given dose of each adenovirus used before 10% FBS-supplemented medium was added.
Recombinant adenoviruses
Construction of the replication-competent Delta-24 adenovirus, with an eight amino-acid deletion in the CR2 domain L 122 TCHEAGF 129 that is responsible for viral E1A binding to the retinoblastoma protein, was described previously. 7 Adenovirus expressing the green fluorescent protein Ad5CMV-GFP, 13 and replication-incompetent Ad5CMV-pA, an E1-deleted adenovirus with an empty expression cassette under the regulation of a cytomegalovirus promoter and a simian virus 40 polyadenylation signal 14 as a control, were used for our infectivity assays. Wild-type adenovirus Ad300, 15 virus inactivated by ultraviolet light (with exposure to 7 cycles of 125J UV light) and mock infections with culture medium were used as controls.
Infectivity assays with Ad5CMV-GFP adenovirus
The Daoy and D283 Med medulloblastoma cell lines were infected with adenovirus expressing GFP at 1, 10, 20, 50 and 100 multiplicities of infection (MOI). At 48 hours after infection of Ad5CMV-GFP, 14 the number of green fluorescent cells was determined from at least 500 cells that demonstrated visibility with interference contrast. The pictures taken after administering increasing doses of Ad5CMV-GFP were acquired using identical settings for gain, contrast, and exposure time. The control infection included nonfluorescent cells only after either the infection with Ad5CMV-pA or the mock infection. The results were expressed as a percentage of green fluorescent cells.
Crystal violet assay
Medulloblastoma Daoy cells, 24 hours after being seeded at the density of 5 Â 10 5 per well in six-well plates, were infected with Ad300, Delta-24, UV-inactivated Delta-24 or Ad300, at 0, 0.1, 1.0, 2.5, 5.0, and 10 MOI. On day 6 of the experiment, they were stained with 0.1% crystal violet in 20% ethanol.
Trypan blue exclusion and MTT assays
Trypan blue experiments were performed as previously described. 12 Briefly, medulloblastoma cell lines were infected with Ad300, Delta-24, UV-inactivated Delta-24 or Ad300 at 0, 1, 5, 10, 20, 50 MOIs and the viable cells were then counted using a hemocytometer. MTT stock solution, sterile, filtered, and protected against light, was prepared at a concentration of 5.5 mg/ml. Daoy and D283 Med medulloblastoma cells were plated at a density of 2 Â 10 3 and 1 Â 10 4 per well in a 96-well plate, respectively, 20 hours before infection. After 6 days, cell viability was assessed via an MTT assay according to the supplier's recommendations Sigma-Aldrich (St Louis, MO).
Preparation of protein samples
Medulloblastoma cells were washed twice with ice-cold PBS and incubated for 1 hour at 41C in RIPA buffer (150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 2% SDS, 20 mM EDTA, and 50 mM Tris, pH 7.4) supplemented with a protease inhibitor cocktail (Sigma-Aldrich, St Louis, MO). The cell lysate protein concentrations were determined using a protein assay kit (Pierce, Rockford, IL) normalized to a standard solution of lyophilized bovine serum gamma globulin.
Western blot analysis of pRb, adenovirus fiber and E2F1 expression
From each sample, 30 mg of protein was subjected to 7.5% SDS-Tris-glycine gel electrophoresis and transferred to a nitrocellulose membrane (Schleider and Schuell Inc., Keene, NH). The membrane was blocked with 3% nonfat milk, 0.05% Tween 20, 0.9% NaCl, and 50 mM Tris, pH 7.5, and incubated with the following primary antibodies: mouse anti-human Rb polyclonal antibody (clone G3-245, dilution 1:1000; BD Biosciences, San Jose, CA), rabbit anti-E2F1 polyclonal antibody (C-20, dilution 1:200; Santa Cruz Biotechnology Inc., Santa Cruz, CA), mouse anti-adenovirus fiber monoclonal antibody Ab-4 (clone 4D2; dilution 1:1000, Neomarkers Inc., Fremont, CA), goat anti-human actin IgG (dilution 1:100; Santa Cruz Biotechnology Inc., Santa Cruz, CA). The secondary antibodies were horseradish peroxidase-conjugated donkey anti-rabbit, goat and mouse IgG (Amersham Corp., Arlington Heights, IL). The membranes were developed according to a standard ECL protocol (Amersham Corp., Arlington Heights, IL).
Flow cytometry analysis of cell cycle and cell receptors
The flow cytometry measurements were produced by an EPICS profile flow cytometer (Coulter Corp., Hialeah, FL) with an air-cooled argon ion laser with an emission wavelength of 488 nm at 15 mW. The analyses included a minimum of 10,000 events per sample. The sub-G1 population was determined prior to the percentage calculations for all cell cycle phases. Cytologic (Coulter Co) and Multicycle (Phoenix Flow System, San Diego, CA) software was used to analyze the results. To assess DNA content, medulloblastoma Daoy cells were cultured in 100 mm plates at a starting density of 5 Â 10 5 per plate, and followed by infection with Delta-24, UV-inactivated Delta-24, wild-type adenovirus Ad300, or PBS alone. The medulloblastoma D283 Med cell line was cultured in 25 ml flasks at a density of 5 Â 10 5 per ml. The infected or control cell cultures were harvested at 3 and 5 days after infection, washed twice with PBS, centrifuged, and stored in 70% ethanol at À201C until being assayed. DNA content was quantified after 15 minutes of incubation with propidium iodide (50 mg/ml) and ribonuclease (20 mg/ml) at 371C.
For assays used to determine cell surface protein expression, medulloblastoma cell lines grown to 85-95% confluence (Daoy) or to a concentration of 1 Â 10 6 cells per ml (D283 Med) were detached with 0.5 mM EDTA in 1 Â PBS, washed twice with cold PBS, and pelleted by centrifugation. Cells were resuspended at a concentration of 1 Â 10 6 cells per ml in blocking buffer (0.5% BSA, 1% calf serum, 1 Â PBS) with anti-integrin a V b 3 or antiintegrin a V b 5 antibodies (clone MAB 1976 anti-human vitronectin receptor a V b 3 and clone MAB1961 antihuman vitronectin receptor a V b 5 , diluted 1:200 and 1:400, respectively, both from Chemicon International, Inc., Temecula, CA), or anti-CAR (clone RmcB diluted 1:2000; Upstate Biotechnology, Lake Placid, NY) and incubated for 2 hours at 41C. Following incubation, the cells were centrifuged and washed with blocking buffer twice. Cells were resuspended again at a concentration of 1 Â 10 6 cells per ml in blocking buffer containing secondary antibody IgG-FITC (fluorescein isothiocyanate-conjugated anti-mouse antibody; Santa Cruz Biotechnology) and incubated for 1 hour at 41C. Cells were then washed two times with PBS and centrifuged. The cell pellet was resuspended in 3.5% paraformaldehyde in PBS for 20 minutes, followed by two washes with PBS, and then resuspended in PBS. FITC fluorescence was assessed with a 525BP filter. The percentage of fluorescent cells was determined in the assays.
Replication assays
Viral production was quantified by a TCID 50 end point dilution assay. Medulloblastoma cell lines were seeded at a density of 5 Â 10 4 per well in six-well plates and 20 hours later were infected with Delta-24 or wild-type adenovirus at 1 MOI. At 3 days post-infection, cell cultures were harvested and lysed by three consecutive freeze-thaw cycles. Cell lysates were clarified by centrifugation and the supernatant was serially diluted in medium for the infection of 293 QBI cells at a density of 3 Â 10 3 per well in 96-well plates. At 10 days after infection, 293 QBI cells were assessed to identify cytopathic effects relative to the respective cell lysate from the original infection. The viral titer was then calculated and expressed as PFU per ml. The following equation was used to attain the viral titer: titer (PFU/ml) ¼ 10 (a þ 0.8) , where a is the sum of fractions of CPE positive wells at consecutive dilutions from 10 À1 to the lowest dilutions with CPE observed based on standard procedure (BD Biosciences, San Jose, CA).
Statistical analysis
In each experiment, the distribution of research parameters was assessed and the statistical tests were chosen based on the test power. Continuous variables were compared with paired t-test. The nonparametric data were compared with a Wilcoxon matched pair test. The differences between the data analyzed were considered significant if the P value was less than .05.
Results
Expression of adenovirus receptors in medulloblastoma cells
The expression of coxsackie adenovirus receptor (CAR) and a v b 5 and a v b 3 cell surface integrins, both associated with the attachment of adenoviral fiber to a target cell, was assessed using flow cytometry analysis. Fig 1a) .
Infectivity of adenovirus in medulloblastoma cells
We assessed the efficiency of adenoviral infection in Daoy and D283 Med medulloblastoma cells using Ad5CMV-GFP at doses of 1-100 MOIs. We observed green fluorescent Daoy cells as early as 24 hours after infection with Ad5CMV-GFP. At 2 days after infection, there was a dose-dependent increase in the percentage of green fluorescent medulloblastoma Daoy cells, which reached the 50% level of total cell number at a MOI of 10 (Fig 1b) . With 50 MOIs, almost all Daoy cells and nearly half of the D283 Med cells expressed exogenous green fluorescence protein (Fig 1b) . The infectivity of adenovirus expressing green fluorescence protein consistently increased with each higher dose used for both Daoy and D283 Med cells (Fig 1c) , as assessed through fluorescence microscopy.
Cytotoxic effects of Delta-24 adenovirus in medulloblastoma cell lines
We next examined the ability of Delta-24 to induce a CPE in medulloblastoma cells. Daily assessment of the infected cultures with light microscopy revealed a progressively increasing CPE that was proportional to the doses of Delta-24 used, ranging from 0.1 to 10 MOIs. Morphologic evaluation showed that the death of cells infected with wild-type adenovirus occurred earlier than when Delta-24 was used. The effect of Delta-24 was readily reproducible in a crystal violet viability test used to assess the CPE. Both mutant Delta-24 and wild-type adenovirus caused complete cell lysis 6 days postinfection at 5 MOIs (Fig  2a) , observations that were confirmed with trypan blue viability tests designed to assess the dose and time patterns of adenovirus cytotoxicity in infected medulloblastoma cells. Trypan blue staining demonstrated a dose-and time-dependent decrease in medulloblastoma cell viability. At an MOI of 1, Delta-24 consistently killed B50% of Daoy medulloblastoma cells compared with B90% killed by wild-type adenovirus 6 days after infection. There were no viable Daoy cells after infection with 20 MOIs of Delta-24 during the same period of time. However, single viable medulloblastoma D283 Med cells remained after the cells were infected with 50 MOIs of Delta-24 for the same length of time. No viable cells were found 8 days after infecting a D283 Med cell line with 20 MOIs of Delta-24, as assessed with a trypan blue test. Trypan blue assays were carried out parallel with MTT tests in the same infected population of cells to confirm the pattern of dosedependent cytotoxicity and to further validate the results related to cytotoxicity. The simultaneous trypan blue and MTT cell viability tests demonstrated consistent, dose-dependent Daoy and D283 Med cell killing by mutant Delta-24 adenovirus (Fig 2b) . In addition, they confirmed that the wild-type adenovirus was only slightly more efficient than mutant Delta-24 at producing cytotoxicity in the medulloblastoma cell lines assessed. These differences were more pronounced in D283 Med cells.
Induction of cell cycle progression by Delta-24 adenovirus
The results from flow cytometric analysis of DNA content demonstrated that the percentage of Daoy medulloblastoma cells in the S phase increased from 18.474.3% in UV-inactivated Delta-24 cells to 53.479.7% compared with 54.275.2% for cells infected with wild-type adenovirus (Fig 3a) . The adenoviral infection of D283 Med cells increased the percentage of cells in the S phase to 43.275.1%, compared with 24.577.3% (P ¼ .01) for the mock infection control 3 days after Delta-24 infection (Fig 3a) . S phase cell entry was further enhanced when the period of time following infection with Delta-24 was extended. In Daoy medulloblastoma cells, the S phase increased to 71.975.5% compared with a control mock infection value of 20.571.4% after 5 days postinfection with 2.5 MOIs of Delta-24 adenovirus. After the same time, the S phase increased to 81.374.5% after the infection with 2.5 MOIs of wild-type adenovirus. Further, the percentage of cells in the sub-G1/G0 phase was increased in a dose-dependent manner in Daoy and D283 Med medulloblastoma cell lines after adenoviral infection with doses ranging from 1 to 50 MOIs. Also, after 5 days, cells in the sub-G0/G1 phase were 5772% of D283 Med cells after infection with wild-type adenovirus and 4872% after infection with Delta-24 adenovirus, compared with 3572% in mock-infected control cells. At 3 days postinfection with 2.5 MOI of Delta-24 in medulloblastoma Daoy cells, Western blot analysis also demonstrated a 105-110 kDa shift in the size of the Rb protein, which is related to changes in phosphorylation status. In parallel, Western blot analyses showed a marked upregulation of E2F1 protein (60 kDa), a downstream component of the Rb pathway, which is required for adenoviral replication (Fig 3b) . The expression of a downstream transcriptional factor and late structural Delta-24 adenoviral proteins observed in these experiments confirmed that the adenovirus replicated by harnessing the cell cycle machinery of the medulloblastoma cells.
Replication of Delta-24 adenovirus in medulloblastoma cells
The replication of Delta-24 adenovirus in Daoy cells was confirmed through an end point dilution assay. At 3 days after Daoy cell cultures were infected with Delta-24 and wild-type adenovirus at 1.0 MOI (equivalent to 5 Â 10 4 PFU/ml with respect to the cell number), the Delta-24 adenovirus titer increased by 2 orders of magnitude compared with the wild-type adenovirus titer that was increased by 3 orders of magnitude in the same cells. Delta-24 adenovirus replicated in medulloblastoma cells, achieving a titer of 10 6.2770.36 PFU/ml in the Daoy cell line. The average titer of Delta-24 adenovirus after Effect of Delta-24 adenovirus against medulloblastoma R Stolarek et al infection of the Daoy medulloblastoma cell line increased from 5 Â 10 4 to 3.16 Â 10 6 PFU/ml, compared with 3.7 Â 10 7 PFU/ml for wild-type adenovirus. The replication of Delta-24 adenovirus in semi-attached D283 cells was equally robust, reaching a mean titer of 2.15 Â 10 6 PFU/ml (Fig 4a) . The replication of the adenovirus was further confirmed by the detection of late structural fiber protein 72 hours after infection of medulloblastoma Daoy cells (Fig 4b) . In contrast, no replication of Delta-24 was detected in human normal astrocytes. Thus, human normal astrocytes were infected with 1 MOI of Delta-24, wild type or ultraviolet inactivated adenovirus and 72 hours later production of viral progeny was titered using TCID 50 . As expected, UV-inactivated adenovirus did not replicate and wild-type adenovirus replicated efficiently (titer 1.9 Â 10 5 and 5.0 Â 10 6 PFU/ml, two independent experiments). Astrocytes infected with Delta-24 produced very low titer of adenovirus (titer 0 and 1.2 Â 10 2 PFU/ml, two independent experiments) demonstrating the poor ability of Delta-24 to replicate in quiescent normal astrocytes.
Discussion
The most relevant observation for future clinical benefit in the present study is that the mutant Delta-24 adenovirus can efficiently infect, replicate and kill medulloblastoma cells, as shown by cytotoxicity and molecular findings. The encouraging oncolytic properties of Delta-24 in medulloblastoma are extended by its ability to effectively infect the target cells. The infectivity of wildtype adenovirus and the E1A mutant Delta-24 have been previously evaluated in different types of normal and cancer cells 7, 9, 16 and we were able to confirm these data in our experimental setting. In the course of infection, even low doses of the Delta-24 adenovirus induced S phase entry of medulloblastoma cells comparable to the effect produced by a related wild-type adenovirus. The mutant Delta-24 adenovirus was also able to utilize the cellular machinery of host medulloblastoma cells to yield extensive production of viral progeny. As expected, the over-representation of cells in S phase correlated with modification of the status of Rb phosphorylation and overexpression of E2F1.
A large body of research suggests that there is a substantial involvement of constitutively activated Effect of Delta-24 adenovirus against medulloblastoma R Stolarek et al pathways whose upregulation could provide constant proliferative stimulation for medulloblastoma cells. These include sonic hedgehog, smoothened, patched, and gli transcriptional factors. [17] [18] [19] [20] Although the molecular mechanism driving p16, Rb, and E2F pathway abnormalities in medulloblastoma cell lines is not yet known, there are indirect research data that substantiate the downregulation of the Rb pathway in medulloblastoma cells. Perturbations of the Rb checkpoint in the cell cycle were indeed observed in a medulloblastoma transgenic mouse model. 21 Furthermore, cyclin D1 and the E2F1 transcriptional factor are partially responsible for mediating sonic hedgehog-elicited tumorigenesis and proliferation. 19 The significant cytotoxicity produced by the successful replication of the Delta-24 mutant E1A adenovirus in medulloblastoma cell lines indicates that the Rb pathway is disrupted in medulloblastomas. The status of the Rb protein is related to the tumor-cell selectivity of the Delta-24 system. In contrast to the permanent downregulation of Rb-controlled cell cycle progression in tumor cells, this checkpoint is only temporarily inactivated in normal cells, a disparity that adds to the functionality of the adenoviral system as a therapeutic tool. Even in a perpetually proliferating cell population under physiologic conditions, such as stem cells and hematopoietic cells, the tumor selectivity of E1A mutant Delta-24 is protected from disruption. Infectivity factors, the low expression of cell surface target receptors for adenoviral infection, and the fact that adenoviral replication in proliferating normal cells was several orders of magnitude less than in cancer cells contribute to the selectivity of the adenoviral system to cancer cells. 9 Currently, we are translating Delta-24 to the clinical setting for the treatment of malignant gliomas. 22 The data in this report indicate that this oncolytic therapy may also be efficacious in patients with medulloblastomas that are resistant to conventional therapy. Adding an oncolytic therapy to the surgical regimen could reduce the presence of cancer cells in the cerebrospinal fluid, particularly since surgery often necessitates postoperative shunting which can transport tumor cells to remote locations. Importantly, this approach may be a valuable addition to surgery in children younger than 4 years, who are routinely treated with lower doses of radiotherapy, and who thus face a higher risk of recurrence and metastasis.
In conclusion, the present findings demonstrating the cytotoxic efficiency of the Delta-24 oncolytic adenovirus combined with the available data elucidating the molecular abnormalities found in human medulloblastoma cells suggest that adenovirus oncolytic therapy can be considered as an option for treating these tumors and could contribute to the most beneficial strategy for managing medulloblastoma. Effect of Delta-24 adenovirus against medulloblastoma R Stolarek et al
